Has Clay Siegall’s Seattle Genetics Transformed Cancer Treatment Approaches?

There is nothing that is more disturbing in the medical world than dealing with cancer. The challenge with the condition is the fact that the available treatment alternatives have been causing more harm than good to the patients. It has been argued that it is not cancer which kills most patients, but the harshness of the chemotherapy. Well, Seattle Genetics Clay Siegall had such an experience when he was a teenager. His father was diagnosed with cancer, and after a six-year-long battle, he succumbed. By the time his father succumbed to cancer, he was 24, but he had already discovered that it was not cancer which killed his father, but the chemotherapy treatment.

He studied Zoology at the University and then proceeded to get a Masters and a Ph.D. in genetics. When he graduated from the University, he worked for some organizations concerned with research into cancer. He at one point worked for the National Cancer Institute. In 1998, he felt that it was time to start his own Biotechnology Company. With the help of a partner, he started Seattle Genetics. The primary mission of the company was to create antibody-based therapies to be used in the treatment of cancer.

The journey has not been easy for Clay Siegall. There was a time when things were so stressful financially that Clay and the management team didn’t have enough to carry out the next phase of a project or even pay salaries to their employees. However, Clay has made severe efforts in creating revenue for the company. He has been a champion for the company’s fundraising drives, both public and private. He has also been forging partnerships with other companies in the same Niche. Seattle Genetics has ADC partnerships with GlaxoSmithKline, Pfizer, and several other organizations. They also held their first IPO in 2001, and the company is listed on NASDAQ.

The future is looking great for Seattle Genetics. They have already gotten one of their drugs approved by the FDA. They are looking forward to performing further tests in 11 other ADC therapies. They hope that they will also manage to get these therapies approved by the FDA. The CEO of the company, Clay, states that they do not have any plans to sell to big pharmaceutical companies. Their interest lies in improving the lives of their patients, and so far, they are doing a great job. Clay Siegall promises that the company will keep doing better each day.

Leave a Reply

Your email address will not be published. Required fields are marked *